Completed PHASE4 INTERVENTIONAL 2-arm NCT04322526

Study of Naltrexone-Induced Blockade of Antidepressant Effects (SONRISA2)

Naltrexone-induced Blockade of Neural Responses Induced by Fast-Acting Antidepressant Effects

Sponsor: Brain & Behavior Research Foundation

Conditions Depression Major Depressive Disorder

Interventions Naltrexone 50 Mg Oral Tablet Placebo oral tablet

Updated 6 times since 2020 Last updated: Apr 10, 2020 Started: Jul 1, 2017 Primary completion: Jul 15, 2018 Completion: Jul 15, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Depression and Major Depressive Disorder and is currently completed. Brain & Behavior Research Foundation leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
May 2020 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Apr 2020 — May 2020 [monthly]

Completed PHASE4

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brain & Behavior Research Foundation
Marta Peciña, MD PhD

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States